GLP-1 Boom Strains Cold Chain: Logistics Giants Race for Capacity

The explosive growth in GLP-1 medication demand—driven by weight-loss and diabetes treatments—is creating unprecedented strain on temperature-controlled logistics infrastructure. Logistics providers globally are scrambling to expand cold storage facilities and specialized handling capabilities to meet surging pharmaceutical volumes. This represents a structural shift in healthcare supply chain requirements, not a temporary spike.

The challenge extends beyond warehousing to last-mile delivery, where maintaining strict temperature controls becomes exponentially more complex. Major logistics operators are investing heavily in cold chain infrastructure, but capacity constraints persist across distribution networks. This bottleneck signals a broader issue: supply chain systems designed for traditional pharmaceutical volumes are fundamentally undersized for the GLP-1 era.

For supply chain professionals, this creates both urgency and opportunity. Companies must reassess their cold chain partnerships, evaluate facility capacity, and potentially diversify logistics providers to ensure GLP-1 product availability. The competitive advantage will go to logistics providers who solve this capacity problem first.